Holly Siegfried

Doctor of Medicine,  The Johns Hopkins Hospital 

Location: Germany

Consulting Services

Legal Support Research Consulting Journal Manuscript Scientific Writing Admin and Customer Support

Areas Of Interest

Portugal Transduced Suicide Gene Emission Spectroscopy, Photoelectron Neonatal Animals Silver Russell Syndrome d-alpha-Tocopheryl Acetate Bryozoas Complement Factor B Fragment, Bb Urachus Posttranslational Modifications Surgical Procedures, Keratorefractive Pacific Transparent Sea Squirt Fermented Milk Products Lactate Transporter Metabolic Brain Diseases, Familial Mason Pfizer monkey virus Rue Concomitant Chemoradiotherapies Cystadenocarcinoma, Serous Genetic Code Viral Occlusion Body Hemorrhage, Biliary Tract Ectopic Pregnancy Cytochrome P450 Family 46 Organomegalies, Polyneuropathy Hepatitis C-Like Virus Fatty Acids, Omega 6 Conversion to an Open Procedure Joint Syndrome, Temporomandibular Zanamivir Abnormality, Cytogenetic Atonic Cerebral Palsy Tachykinin Receptor p100 GAP Astrophysical Concept

Professional Narrative

Dr. Holly Siegfried was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Siegfried has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.


Employment

Assistant Professor, Mayo Clinic 1994
Assistant Professor, Harvard Med 2000

Education

Bachelor of science in nursing, Weill Medical College 1990
Doctor of medicine, Harvard Medical School 2006

Referees


Publications

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Yin X, Mead BE, Safaee H, Langer R, Karp JM, Levy O. Engineering Stem Cell Organoids. Cell Stem Cell. 2016 Jan 7;18(1):25-38. doi: 10.1016/j.stem.2015.12.005. PMID: 26748754; PMCID: PMC4728053.

Yin X, Mead BE, Safaee H, Langer R, Karp JM, Levy O. Engineering Stem Cell Organoids. Cell Stem Cell. 2016 Jan 7;18(1):25-38. doi: 10.1016/j.stem.2015.12.005. PMID: 26748754; PMCID: PMC4728053.


Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :


Languages

Language Proficiency :

Translation Services :